Tin tức & Cập nhật
Lọc theo Chuyên ngành:

TrUST study heralds new era for TB diagnosis
A suite of deep learning (DL) models to automate tuberculosis (TB) risk assessment from lung ultrasound (LUS) images fulfils the WHO criteria for a sputum-free TB triage test and outwits human experts in the TrUST study.
TrUST study heralds new era for TB diagnosis
21 May 2025
Meta-analysis strengthens case for awake prone positioning in COVID-19 with AHRF
Placing awake COVID-19 patients with acute hypoxaemic respiratory failure (AHRF) in a prone position is an efficacious intervention in terms of both reducing mortality and preventing intubation, according to an individual participant data meta-analysis.
Meta-analysis strengthens case for awake prone positioning in COVID-19 with AHRF
17 May 2025
Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19
Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.
Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19
16 May 2025
EGFR-related skin AE rates drop with COCOON regimen
Interim data from the phase II COCOON trial demonstrate the potential of the COCOON dermatologic management (DM) regimen to significantly reduce the incidence and severity of dermatologic adverse events (dAEs) tied to amivantamab plus lazertinib treatment in patients with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).
EGFR-related skin AE rates drop with COCOON regimen
14 May 2025
MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC
In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).